Brief: Cyteir Therapeutics Reports First Quarter 2023 Financial Results And Operational Highlights
10/05/2023 22:11
May 10 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* CYTEIR THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND OPERATIONAL HIGHLIGHTS
* Q1 LOSS PER SHARE $0.35
* ENROLLMENT CONTINUING IN TRIALS WITH CYT-0851 IN
COMBINATION
WITH CAPECITABINE OR GEMCITABINE WITH DATA EXPECTED IN MID-2023
* ENDED Q1 OF 2023 WITH APPROXIMATELY $137.2 MILLION IN CASH
* QTRLY LOSS PER SHARE $0.35
* CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2023 ARE
EXPECTED TO
FUND PLANNED OPERATIONS INTO 2026
* Q1 EARNINGS PER SHARE VIEW $-0.27 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw9FDN1ca
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile